{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:06:29Z","timestamp":1784333189573,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T00:00:00Z","timestamp":1728777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T00:00:00Z","timestamp":1728777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008615","name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["P30CA016086"],"award-info":[{"award-number":["P30CA016086"]}],"id":[{"id":"10.13039\/100008615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008615","name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["P30CA016086"],"award-info":[{"award-number":["P30CA016086"]}],"id":[{"id":"10.13039\/100008615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008615","name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["P30CA016086"],"award-info":[{"award-number":["P30CA016086"]}],"id":[{"id":"10.13039\/100008615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008615","name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["P30CA016086"],"award-info":[{"award-number":["P30CA016086"]}],"id":[{"id":"10.13039\/100008615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008615","name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["P30CA016086"],"award-info":[{"award-number":["P30CA016086"]}],"id":[{"id":"10.13039\/100008615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008615","name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["P30CA016086"],"award-info":[{"award-number":["P30CA016086"]}],"id":[{"id":"10.13039\/100008615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008615","name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["P30CA016086"],"award-info":[{"award-number":["P30CA016086"]}],"id":[{"id":"10.13039\/100008615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008615","name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["P30CA016086"],"award-info":[{"award-number":["P30CA016086"]}],"id":[{"id":"10.13039\/100008615","id-type":"DOI","asserted-by":"publisher"}]},{"name":"national inst","award":["K08CA280388"],"award-info":[{"award-number":["K08CA280388"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s10549-024-07500-w","type":"journal-article","created":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T23:02:37Z","timestamp":1728860557000},"page":"367-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Trends in management and related outcomes for occult primary breast cancer"],"prefix":"10.1007","volume":"209","author":[{"given":"M.","family":"LaBella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. E.","family":"Lile-King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. B.","family":"Agala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. M.","family":"Spanheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. W.","family":"Ollila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. K.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Selfridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,13]]},"reference":[{"issue":"2","key":"7500_CR1","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/archsurg.1990.01410140088014","volume":"125","author":"PL Baron","year":"1990","unstructured":"Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA (1990) Occult breast cancer presenting with axillary metastases. Updat Manage Arch Surg 125(2):210\u2013214. https:\/\/doi.org\/10.1001\/archsurg.1990.01410140088014","journal-title":"Updat Manage Arch Surg"},{"issue":"10","key":"7500_CR2","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1245\/s10434-017-5928-x","volume":"24","author":"LK Hessler","year":"2017","unstructured":"Hessler LK, Molitoris JK, Rosenblatt PY et al (2017) Factors influencing management and outcome in patients with occult breast cancer with axillary lymph node involvement: analysis of the national cancer database. Ann Surg Oncol 24(10):2907\u20132914. https:\/\/doi.org\/10.1245\/s10434-017-5928-x","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"7500_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-018-4898-4","volume":"172","author":"M Terada","year":"2018","unstructured":"Terada M, Adachi Y, Sawaki M et al (2018) Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes. Breast Cancer Res Treat 172(1):1\u20137. https:\/\/doi.org\/10.1007\/s10549-018-4898-4","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"7500_CR4","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1245\/s10434-017-5965-5","volume":"24","author":"DP McCartan","year":"2017","unstructured":"McCartan DP, Zabor EC, Morrow M, Van Zee KJ, El-Tamer MB (2017) Oncologic outcomes after treatment for MRI occult breast cancer (pT0N+). Ann Surg Oncol 24(11):3141\u20133147. https:\/\/doi.org\/10.1245\/s10434-017-5965-5","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"7500_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejso.2009.09.007","volume":"36","author":"J de Bresser","year":"2010","unstructured":"de Bresser J, de Vos B, van der Ent F, Hulsew\u00e9 K (2010) Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. Eur J Surg Oncol 36(2):114\u2013119. https:\/\/doi.org\/10.1016\/j.ejso.2009.09.007","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"7500_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10434-000-0411-4","volume":"7","author":"JA Olson Jr","year":"2000","unstructured":"Olson JA Jr, Morris EA, Van Zee KJ, Linehan DC, Borgen PI (2000) Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 7(6):411\u2013415. https:\/\/doi.org\/10.1007\/s10434-000-0411-4","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"7500_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1148\/radiology.205.2.9356625","volume":"205","author":"EA Morris","year":"1997","unstructured":"Morris EA, Schwartz LH, Dershaw DD, van Zee KJ, Abramson AF, Liberman L (1997) MR imaging of the breast in patients with occult primary breast carcinoma. Radiology 205(2):437\u2013440. https:\/\/doi.org\/10.1148\/radiology.205.2.9356625","journal-title":"Radiology"},{"issue":"1","key":"7500_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1245\/s10434-014-3991-0","volume":"22","author":"NM Rueth","year":"2015","unstructured":"Rueth NM, Black DM, Limmer AR et al (2015) Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol 22(1):90\u201395. https:\/\/doi.org\/10.1245\/s10434-014-3991-0","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"7500_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.amjsurg.2005.06.026","volume":"190","author":"AK Khandelwal","year":"2005","unstructured":"Khandelwal AK, Garguilo GA (2005) Therapeutic options for occult breast cancer: a survey of the American Society of Breast Surgeons and review of the literature. Am J Surg 190(4):609\u2013613. https:\/\/doi.org\/10.1016\/j.amjsurg.2005.06.026","journal-title":"Am J Surg"},{"issue":"6","key":"7500_CR10","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1245\/s10434-016-5104-8","volume":"23","author":"FI Macedo","year":"2016","unstructured":"Macedo FI, Eid JJ, Flynn J, Jacobs MJ, Mittal VK (2016) Optimal surgical management for occult breast carcinoma: a meta-analysis. Ann Surg Oncol 23(6):1838\u20131844. https:\/\/doi.org\/10.1245\/s10434-016-5104-8","journal-title":"Ann Surg Oncol"},{"issue":"18","key":"7500_CR11","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.7150\/jca.21217","volume":"8","author":"SG Wu","year":"2017","unstructured":"Wu SG, Zhang WW, Sun JY et al (2017) Comparable survival between additional radiotherapy and local surgery in occult breast cancer after axillary lymph node dissection: a population-based analysis. J Cancer 8(18):3849\u20133855","journal-title":"J Cancer"},{"issue":"3","key":"7500_CR12","first-page":"138","volume":"5","author":"BS Laughlin","year":"2018","unstructured":"Laughlin BS, Ehsani S, Chalasani P, Gonzalez V (2018) Oncologic outcomes with neoadjuvant chemotherapy and breast conservation for MRI occult breast cancer. Arch Breast Cancer 5(3):138\u2013143","journal-title":"Arch Breast Cancer"},{"issue":"5","key":"7500_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10434-001-0425-6","volume":"8","author":"G Vlastos","year":"2001","unstructured":"Vlastos G, Jean ME, Mirza AN et al (2001) Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol 8(5):425\u2013431. https:\/\/doi.org\/10.1007\/s10434-001-0425-6","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"7500_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10549-019-05285-x","volume":"177","author":"HM Johnson","year":"2019","unstructured":"Johnson HM, Irish W, Vohra NA, Wong JH (2019) The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2\/N3): a population analysis. Breast Cancer Res Treat 177(1):155\u2013164. https:\/\/doi.org\/10.1007\/s10549-019-05285-x","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"7500_CR15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.4048\/jbc.2013.16.4.410","volume":"16","author":"SM Woo","year":"2013","unstructured":"Woo SM, Son BH, Lee JW et al (2013) Survival outcomes of different treatment methods for the ipsilateral breast of occult breast cancer patients with axillary lymph node metastasis: a single center experience. J Breast Cancer 16(4):410\u2013416. https:\/\/doi.org\/10.4048\/jbc.2013.16.4.410","journal-title":"J Breast Cancer"},{"issue":"3","key":"7500_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/jso.23644","volume":"110","author":"G Sohn","year":"2014","unstructured":"Sohn G, Son BH, Lee SJ et al (2014) Treatment and survival of patients with occult breast cancer with axillary lymph node metastasis: a nationwide retrospective study. J Surg Oncol 110(3):270\u2013274. https:\/\/doi.org\/10.1002\/jso.23644","journal-title":"J Surg Oncol"},{"key":"7500_CR17","doi-asserted-by":"publisher","first-page":"1051232","DOI":"10.3389\/fonc.2023.1051232","volume":"13","author":"R Wang","year":"2023","unstructured":"Wang R, Yang HX, Chen J, Huang JJ, Lv Q (2023) Best treatment options for occult breast cancer: a meta-analysis. Front Oncol 13:1051232","journal-title":"Front Oncol"},{"issue":"17","key":"7500_CR18","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1002\/cncr.25197","volume":"116","author":"GV Walker","year":"2010","unstructured":"Walker GV, Smith GL, Perkins GH et al (2010) Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer 116(17):4000\u20134006. https:\/\/doi.org\/10.1002\/cncr.25197","journal-title":"Cancer"},{"issue":"14","key":"7500_CR19","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/j.ejca.2011.05.010","volume":"47","author":"SR Barton","year":"2011","unstructured":"Barton SR, Smith IE, Kirby AM, Ashley S, Walsh G, Parton M (2011) The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. Eur J Cancer 47(14):2099\u20132106. https:\/\/doi.org\/10.1016\/j.ejca.2011.05.010","journal-title":"Eur J Cancer"},{"key":"7500_CR20","unstructured":"National comprehensive cancer network. Breast cancer (Version 1.2024). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf2.2019). Accessed March 10, 2024."},{"issue":"6","key":"7500_CR21","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1245\/s10434-020-08227-w","volume":"27","author":"BL Cohen","year":"2020","unstructured":"Cohen BL, Collier AL, Kelly KN et al (2020) Surgical management of the axilla in patients with occult breast cancer (cT0 N+) after neoadjuvant chemotherapy. Ann Surg Oncol 27(6):1830\u20131841. https:\/\/doi.org\/10.1245\/s10434-020-08227-w","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"7500_CR22","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1245\/s10434-020-08863-2","volume":"28","author":"A Botty Van den Bruele","year":"2021","unstructured":"Botty Van den Bruele A, Lavery J, Plitas G, Pilewskie ML (2021) Axillary downstaging in occult primary breast cancer after neoadjuvant chemotherapy. Ann Surg Oncol 28(2):968\u2013974","journal-title":"Ann Surg Oncol"},{"issue":"14","key":"7500_CR23","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310(14):1455\u20131461. https:\/\/doi.org\/10.1001\/jama.2013.278932","journal-title":"JAMA"},{"issue":"7","key":"7500_CR24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14(7):609\u2013618. https:\/\/doi.org\/10.1016\/S1470-2045(13)70166-9","journal-title":"Lancet Oncol"},{"issue":"3","key":"7500_CR25","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M et al (2015) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 33(3):258\u2013264. https:\/\/doi.org\/10.1200\/JCO.2014.55.7827","journal-title":"J Clin Oncol"},{"issue":"3","key":"7500_CR26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","volume":"15","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Stewart AK, Winchester DP, Ko CY (2008) The national cancer data base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15(3):683\u2013690. https:\/\/doi.org\/10.1245\/s10434-007-9747-3","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"7500_CR27","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1245\/s10434-019-07213-1","volume":"26","author":"K Mallin","year":"2019","unstructured":"Mallin K, Browner A, Palis B et al (2019) Incident cases captured in the national cancer database compared with those in U.S. population based central cancer registries in 2012-2014. Ann Surg Oncol 26(6):1604\u20131612","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"7500_CR28","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318(10):918\u2013926. https:\/\/doi.org\/10.1001\/jama.2017.11470","journal-title":"JAMA"},{"issue":"4","key":"7500_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Cole BF, Zurrida S et al (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23\u201301): a phase 3 randomised controlled trial [published correction appears in lancet oncol. Lancet Oncol 14(4):297\u2013305. https:\/\/doi.org\/10.1016\/S1470-2045(13)70035-4","journal-title":"Lancet Oncol"},{"issue":"12","key":"7500_CR30","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303\u20131310. https:\/\/doi.org\/10.1016\/S1470-2045(14)70460-7","journal-title":"Lancet Oncol"},{"issue":"6","key":"7500_CR31","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1089\/lrb.2021.0033","volume":"20","author":"Y Hara","year":"2022","unstructured":"Hara Y, Otsubo R, Shinohara S et al (2022) Lymphedema after axillary lymph node dissection in breast cancer: prevalence and risk factors-a single-center retrospective study. Lymphat Res Biol 20(6):600\u2013606. https:\/\/doi.org\/10.1089\/lrb.2021.0033","journal-title":"Lymphat Res Biol"},{"issue":"9","key":"7500_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jnci\/djj158","volume":"98","author":"RE Mansel","year":"2006","unstructured":"Mansel RE, Fallowfield L, Kissin M et al (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98(9):599\u2013609. https:\/\/doi.org\/10.1093\/jnci\/djj158","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"7500_CR33","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34(10):1072\u20131078. https:\/\/doi.org\/10.1200\/JCO.2015.64.0094","journal-title":"J Clin Oncol"},{"issue":"4","key":"7500_CR34","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/XCS.0000000000000098","volume":"234","author":"KK Gallagher","year":"2022","unstructured":"Gallagher KK, Iles K, Kuzmiak C, Louie R, McGuire KP, Ollila DW (2022) Prospective evaluation of radar-localized reflector-directed targeted axillary dissection in node-positive breast cancer patients after neoadjuvant systemic therapy. J Am Coll Surg 234(4):538\u2013545. https:\/\/doi.org\/10.1097\/XCS.0000000000000098","journal-title":"J Am Coll Surg"},{"issue":"4","key":"7500_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","volume":"3","author":"M Pilewskie","year":"2017","unstructured":"Pilewskie M, Morrow M (2017) Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol 3(4):549\u2013555. https:\/\/doi.org\/10.1001\/jamaoncol.2016.4163","journal-title":"JAMA Oncol"},{"issue":"40","key":"7500_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008200","volume":"96","author":"H Yang","year":"2017","unstructured":"Yang H, Li L, Zhang M, Zhang S, Xu S, Ma X (2017) Application of neoadjuvant chemotherapy in occult breast cancer: five case reports. Medicine (Baltimore) 96(40):e8200. https:\/\/doi.org\/10.1097\/MD.0000000000008200","journal-title":"Medicine (Baltimore)"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07500-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07500-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07500-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T20:22:42Z","timestamp":1738354962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07500-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,13]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["7500"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07500-w","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,13]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Given the use of the National Cancer Database, the University of North Carolina IRB has found this study to be exempt (IRB# 20\u20131493).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}